anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a skin temperature-increasing agent giving a warm feeling to skin by increasing skin temperature, preventing or moderating the oversensitivity to cold and cold feeling, and further activating the metabolism of skin by including a specific phthalide derivative or its salt as an active component. CONSTITUTION: This skin temperature-increasing agent contains a phthalide derivative or a salt thereof expressed by the formula (R<1> is H, OH, methoxy, amino or dimethylamino; R<2> and R<3> are each H or methoxy; R<4> is H, amino or dimethylamino; R<5> is H, an alkyl or an alkoxy; R<6> is H or an alkyl) (e.g. 3-octylphthalide) as an active component. The phthalide derivative or the salt thereof expressed by the formula may also be, e.g. an organic solvent extract with ethanol or hot water, etc., from a plant of family Apiaceae. Otherwise, it may also be synthesized by obtaining an alkylidene phthalide derivative, by a heating reaction of a phthalic acid anhydride derivative with an acid anhydride, followed by hydrogenation.  The skin temperature-increasing agent induces effects such as recovery from fatigue, improvement of beautifulness, prevention of aging and increasing of drug penetration into the skin.
Participants first received Abdominal drawing-in maneuver exercise 2 times a week for 4 weeks. Each session is 40 minutes for additional 10 min with conventional therapy. Afterward a washout period of one month, they then received sham therapy (conventional therapy_release pain or upper limb mobilization) 2 times a week for 4 weeks. Each session is 40 minutes.
<P>PROBLEM TO BE SOLVED: To obtain a medicine, a health food and a nutritional medicine composition each of which can improve the oral absorption of glucosaminoglycan or its salt, can enhance its original medicinal effects, and quickly exhibits the effects.  <P>SOLUTION: The oral administration medicine, health food or nutritional medicine composition is characterized by comprising one or more compounds selected from the group consisting of glucosaminoglycan or its salts and one or more compounds selected from the group consisting of saponin and its salts. The glucosaminoglycan or its salts include hyaluronic acid, hyaluronate, dermatan sulfuric acid, dermatan sulfate, chondroitin, chondroitin sulfuric acid, and chondroitin sulfate. The saponin is preferably soybean saponin. The mass ratio of one or more compounds selected from the group consisting of glucosaminoglycan and its salts: one or more compounds selected from the group consisting of saponin and its salts is preferably 1:0.0001 to 2.  <P>COPYRIGHT: (C)2004,JPO
The purpose of this prospective randomized double-blind study is to determine if the novel technique of ultrasound guided peri-arterial injection of local anesthetic around the femoral artery decreases ischemic hypertension associated with prolonged lower extremity tourniquet time during total ankle arthroplasty (TAA) and foot fusion surgeries. Efficacy will be determined by analyzing incidence of intraoperative ischemic hypertension, defined as \>30% increase in systolic blood pressure, associated with tourniquet inflation times greater than 90 minutes. The study will involve a total of 30 patients (15 in each group) and with a power of 80% to detect a 50% difference. The patients involved in the study will be ASA 1-3 patients who are undergoing either TAA or foot fusion surgeries. Patients will receive standard of care for their anesthesia, which at Duke Hospital includes placement of popliteal and saphenous perineural catheters and a general anesthetic with a laryngeal mask airway. Patients will be randomized to receive femoral peri-arterial injection with either 1.5% mepivacaine with 1:400,000 epinephrine or 0.9% saline which will be performed preoperatively at time of perineural catheter placement. Patients will assume standard risk associated with nerve blocks, including theoretical risk of nerve damage and local anesthetic systemic toxicity. Possible benefits include improved intraoperative hemodynamic stability, decreased intraoperative opioid and antihypertensive medications, and decreased tourniquet associated pain post-operatively.
Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
Participants who report typically smoking menthol cigarettes will be invited to complete a session. Participants will undergo overnight tobacco/nicotine abstinence before the visit (eCO\<12ppm). Participants will then be randomized 1:1 to e-cigarette flavor order (tobacco e-cigarette, menthol e-cigarette). They will complete a 30-minute ad libitum session with the first product, based on randomization, followed by a 1.5 hour standard washout period, followed by a 30-minute ad libitum vaping session with the second product. Throughout each session, puff topography will be measured via a pressure sensor attached to the e-cigarette device. Participants will complete self-report measures of smoking urges and withdrawal symptoms pre- and post-vaping session. In addition, they will complete measures of subjective vaping experience, perceptions of flavor, product demand, and intentions for future use.
Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
The invention discloses a traditional Chinese medicine composition with the effect of reducing blood sugar. The traditional Chinese medicine composition is prepared from the following active ingredients in parts by weight: 30-40 parts of membranous milkvetch root, 20-30 parts of sungrass, 15-25 parts of herb of goldencup St. John wort, 15-25 parts of Indian buead, 8-12 parts of largehead atractylodes rhizome and 8-12 parts of liquorice root. The traditional Chinese medicine composition can be in the form of granules, tablets, oral liquid and capsules. The invention further discloses a preparation method of the traditional Chinese medicine composition. The preparation method comprises the following steps: adding water for decoction, concentrating, performing alcohol precipitation, performing spray-drying, and adding auxiliary materials to prepare the composition. The invention also discloses application of the traditional Chinese medicine composition to preparation of medicaments with the effect of reducing blood sugar.
BACKGROUND: Obesity is expected to hinder efferocytosis due to ADAM17-mediated cleavage of the MER tyrosine kinase receptor, producing soluble MER (sMER) that disrupts MERTK binding to cell death markers. However, the intracellular efferocytosis pathway in central obesity remains elusive, particularly the role of low-grade chronic inflammation in its initiation and identification of binding signals that disrupt efferocytosis.
OBJECTIVE: We investigate the efferocytosis signaling pathway in men with central obesity and its relationship with inflammation, cell death, and related processes.
METHODS: A cross-sectional study was conducted, and clinical data and blood samples were collected from 56 men with central obesity (obese group) and 29 nonobese individuals (control group). Clinical evaluations and predefined biochemical screening tests were performed. The efferocytosis signaling pathway was investigated by measuring phosphatidylserine (PS), ADAM17, TNF-alpha (TNF-α), and sMER.
RESULTS: Metabolic syndrome was detected in more than half of the participants in the obese group according to the predefined tests. Mean levels of PS, TNF-α, and sMER were higher in the obese group but not significantly different from those of the control group. Further analysis based on waist circumference (WC) ranges in the obese group revealed a significant increase in PS and sMER levels between the control group and the obese group with WC greater than 120 cm. ADAM17 levels were significantly higher in the obese group than in the control group. PS was positively correlated with WC and ADAM17. ADAM17 was positively correlated with TNF-α and sMER, indicating impaired efferocytosis.
CONCLUSIONS: Central obesity appeared to cause a disturbance in efferocytosis that began with cell damage and death, along with an enlargement of the WC and an ongoing inflammatory response. Efferocytosis was disrupted by proinflammatory cytokine regulators, which induced the production of sMER and interfered with the efferocytosis process.
Premature ventricular complex is a very frequent arrhythmia. Suggested mechanisms for PVCs are reentry, triggered activity, and enhanced automaticity. Enhanced automaticity process is the underlying mechanism for arrhythmias due to excess catecholamines. Catecholamines may increase in patients with PVC. Half-lives of catecholamines are very short and rather changeable. Therefore, 24 hours urine levels of catecholamines are the more sensitive than plasma levels. Metabolites of catecholamines are metanephrine and normetanephrine. Our aim is to measure 24 hours urine levels of metanephrine and normetanephrine.
Participants will receive placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of placebo; participants 12 years and older will receive placebo tablets.
FIELD: organic chemistry. SUBSTANCE: product: N-phenyl-2-cyano-3-hydroxycrotonic acid amide of the formula (I) given in description where: R 1  - hydrogen; R 3  - lower alkyl; R 2  - halogen, nitro, cyano, trifluoromethyl. Synthesis: interaction of reagent 2 with reagent 3 of formulas given in description where Z means halogen atom followed by treatment of the synthesized compound with a base. Drug showing antiinflammatory activity has an active substance (I) and additions, shows immunomodulating effect and can be used in pharmaceutical industry. EFFECT: improved method of synthesis. 5 cl, 4 tbl
The proposed research employs the Integrated Behavior Model (IBM) to address fundamental drivers of behavior for older rural-dwelling adults with type-two diabetes mellitus (T2DM) in the context of their social network. Social network analysis (SNA) is characterized as the examination and interpretation of relational connections. This approach can be used to map social networks and understand relationships between individuals as it pertains to social support. Snowball recruitment methods will be used to recruit participants in this study. In Aim 1, individuals who are connected to several individuals within their community and have the capacity to influence norms that hinder T2DM self-care will be identified. Ten individuals who have received medical care from the Center of Excellence in Rural Health (CERH) within the past 12 months will be identified. Initial recruitment will be conducted by a community liaison in Leslie County. This core group of 10 "seeds" will be used to conduct the first wave of interviews. Since the aim of social network analysis is to understand a community by mapping the relationships that connect them as a network, each seed will be asked to identify 3 persons believed to be influential in their community. Those who are identified in wave 1 will also be asked to identify 3 people each from their community who are also respected as leaders and can be trusted to provide health-related information to community members. This process will continue for 4 waves of recruitment (N˜200).

Participants will be asked to provide demographic information including age, sex, race/ethnicity, education, employment status, contact information (address, telephone number, email). An interview guide will be adapted from a previously published intervention assessing social networks and health behavior informed by preliminary data and the expert opinion of my team of mentors and collaborators. The interviews will begin with two broad general questions asking "who" is included in their social network and "how" members of the social network provide social support; using open-ended questions to elicit maximal information with minimal bias. Interview questions will explore the following domains: size and structure of social network; resources available through social network; beliefs of those in social network regarding general healthy behavior; knowledge of available healthy lifestyle choices; and perceived acceptable healthy behaviors (social norms). Data will be collected from CHWs pre- and post-training to assess the following: T2DM knowledge: Diabetes Knowledge Questionnaire (DKQ) a 24-item survey that has a reliability coefficient of 0.78 and showed sensitivity to a T2DM knowledge intervention. Health literacy: Newest Vital Sign (NVS) is a 6-item survey to assess health literacy comprehension and numeracy. Means and paired t-tests will be conducted to determine if health literacy and T2DM knowledge improved in each CHW during the DEEP training.
<P>PROBLEM TO BE SOLVED: To provide a new cosmetic composition for a pack retaining skin moisture over a long period of time and imparting a nutritive ingredient and a functional ingredient to the skin over the long period of time during make-up without the need of washing off or peeling the pack after forming a thin film by high water solubility and excellent transparency and adhesiveness to the skin.  <P>SOLUTION: A film formed by using a porphyran as a principal material of the cosmetic pack has the ultrahigh water solubility, excellent transparency and adhesiveness to the skin and forms an ultrathin film with little sense of incompatibility on the skin surface. Thereby, there is no need of peeling or washing off the film. The pack of the ultrathin film forms the ultrathin film naturally assimilating with the skin surface without the sense of incompatibility with the skin and is retaining an active ingredient of the skin and a humectant ingredient on the skin over the long period of time. Since the film of the pack forms a transparent thin film without cloudiness, a cosmetic, an emulsion, make-up powder etc. , can be applied from the upper part of the film of the pack.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Provided is a system providing a solution for improving prescription drug compliance monitoring and compliance. Prescription drug compliance monitoring may be achieved by using patient's electronic device to initiate secure digital imaging. Medications may be dispensed in containers with pre-printed encoded unique identifiers and markings. The patient may use the digital camera in their smart phone to take a picture of the dispensed blister pack which may be processed and analyzed. Analysis may include assessment of the number of pills taken from and remaining in the uniquely identified blister pack. Package identification and consumption information may then be linked with other prescription information to determine if the observed rate of use is compliant with the legal prescription and to document that the imaged medication package is the same as the dispensed medication package. Data may also be linked with pharmacologic and clinical data to categorize risk and urgency of misuse.
The invention relates to the application of water hyacinth extractive in preparing lipid-lowering medicaments and the preparation method of the water hyacinth extractive. The water hyacinth extractive is the extractive of stems, leaves and/or roots of Eichhornia crassipes (Mart.Solms) which belongs to the Pontederiaceae plant, and the extraction solvent adopts water or the organic solvent with medium polarity to large polarity, such as chloroform, ethyl acetate, acetone, methanol, ethanol and normal butanol. The water hyacinth extractive can also be the extracted fresh juice or the dried products of the extracted fresh juice of stems, leaves and/or roots of water hyacinth. The water hyacinth extractive has the effects of reducing blood lipid and preventing fatty liver. The water hyacinth extractive can be prepared into the preparation which is clinically acceptable, and can be applicable to the treatment of lipid disorder caused by various diseases for reducing blood lipid or to the treatment of the fatty liver patients for preventing fatty liver. The water hyacinth extractive can also be prepared into health-care products, food or food additives so as to be applicable to the health care of the specific population.
This is a single-arm interventional study. After acceptance of the study (signature of the informed consent form), patients are included in the single-arm interventional study for a period of 12 months with follow-up visits every 3 months and intermediate visits in the case of the symptoms presence or sexual contacts with partners having STIs (corresponding to standard care for the PrEP users).
Hypotension — Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION.)  
Agents Causing Renin Release: The antihypertensive effect of enalapril maleate is augmented by antihypertensive agents that cause renin release (e.g., diuretics).  
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function. These effects are usually reversible.   
In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.   
Other Cardiovascular Agents: Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.  
Agents Increasing Serum Potassium: Enalapril maleate attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Potassium sparing agents should generally not be used in patients with heart failure receiving enalapril maleate.   
Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril maleate and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.  
Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including Enalapril.
Recently, coronary angiography (CAG) and percutaneous coronary intervention (PCI) via the distal radial artery access (DRA) have shown several advantages owing to fewer complications, such as radial artery occlusion, pseudoaneurysms, and arteriovenous(AV) fistulas, and short hemostasis duration than the proximal radial access (PRA). However, despite the potential advantages of the DRA, there are still many cardiologists who prefer the femoral approach for complex PCI including left main disease, bifurcation lesions, heavily calcified lesions, which need a strong backup and using several devices. The radial artery and the distal radial artery have a smaller diameter than the femoral artery, and interventional cardiologists are usually performed using the 6-Fr sheath. The previously developed 7-Fr sheath has a higher risk of vascular occlusion when use in a radial artery due to larger diameter compared to radial artery in 30% to 60% of patients. However, with the recent development of various technologies, the outer diameter of the sheath is gradually becoming thinner and recently a 7-Fr thin-walled sheath which does not differ significantly from the outer diameter of the 6-Fr sheath used in the previously PRA demonstrated that feasibility and safety for radial artery intervention. Despite the feasibility and potential benefits of the DRA and 7-Fr thin-walled sheath for radial artery, there is a lack of data regarding the safety and efficacy of a 7-Fr thin-walled sheath during the DRA.
FIELD: medicine. SUBSTANCE: one should carry out both phyto- and hirudotherapy for a patient, moreover, hirudotherapy is conducted by the course of 10-25 seances in 1-10 d by putting about 5-15 leech/seance onto the sites chosen out of the group: vaginal arch, perineum, anus, and acupuncture points above the projection of liver, spleen, adrenal glands, pancreas, thyroid gland. As for phytotherapy, it is performed either before hirudotherapy or simultaneously with it for 1-3 mo. Phytotherapy includes the intake of plant-origin tinctures containing about 0.5-10% common sweet clover at 15-30 g dry raw material/daily dosage. EFFECT: higher efficiency of therapy. 4 cl, 3 ex
Phase 3: (Post Intervention observation phase): The final phase of the study will be again three (3) months. The intervention of feedback emails and text pages will be discontinued and the study participants will only be monitored to see if the past intervention made an impact on their daily clinical practice in terms of time spent with the patients.
Participants will receive 3 cycles of pembrolizumab regardless of PD-L1 status. After completion of the second cycle of pembrolizumab treatment, and just before the third injection of pembrolizumab an 18FDG-PET/CT scan will be performed to assess a potential metabolic response. Then between 2 to 4 weeks after the third treatment, subjects will undergo radical prostatectomy. Subjects will be followed every 3 months during the first year post-surgery and according to physician decision during the following years.
The health coaching intervention group (n=100) will receive written educational materials on diabetes self-management in Spanish and the diabetes self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish). In addition, patients in the intervention group will be assigned a health coach who will provide health coaching over the course of 6 months with 14 phone calls.